Kent Alan Gossett

GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California.

Protez Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It develops antibiotics for infections & provides research service on intravenous & oral small molecule antibiotics to chronic and recurrent infections. The company was founded by Klaus Esser, Luigi Xerri & Christopher M. Cashman in 2003 and is headquartered in Malvern, PA.

Clinical Pathology Laboratories, Inc. owns and operates pathology laboratories. It performs comprehensive clinical and anatomical testing for physicians, hospitals, and managed-care organizations. The company was founded by Charles F. Pelphrey on May 1, 1948 and is headquartered in Austin, TX.

GlaxoSmithKline Research & Development manufactures pharmaceutical products. It has locations in the U.S. and across Europe. The company has treatments in the works for therapies such as infectious diseases, neuroscientific requirements and respiratory needs. GlaxoSmithKline is located in Research Triangle Park, NC

Part of GSK Plc, Sterling Winthrop, Inc. is a company that specializes in cameras and duplicating machines. The company is based in Rochester, NY. Sterling Winthrop was acquired by GSK Plc from Eastman Kodak Co. on November 03, 1994 for $2,930 million.

MicroMass Communications, Inc. provides healthcare communications services. Its services include patient engagement and support, relationship marketing, precommercial and clinical, and health behavior consulting. The company was founded by David W. Bulger, Wayne Bulger and Mark Rinehart in 1994 and is headquartered in Cary, NC.

Protein Forest, Inc., a privately held company founded in 2002 and is located in Lexington, MA, is a developer and manufacturer of state-of-the-art sample fractionation technology, products, and data analysis software for mass spectrometry. The company develops, manufactures, and markets instruments, consumables, and bioinformatics software products for scientists in the life science, drug discovery, pharmaceutical, biotech, and diagnostic industries around the world.

Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase.